TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02501161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
Study: NCT04027179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate mouthwash
Description: 0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation
Description: Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal instrumentation
Description: Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal instrumentation
Description: Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
Study: NCT02135016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Description: epidural anesthesia with 1% lidocaine 10ml before propofol TCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: epidural anesthesia with 2% lidocaine 5ml before propofol TCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
Study: NCT00824655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 13vPnC will be administered by intramuscular injection at approximately 12 months of age.
Study: NCT01718587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation through interventional procedure
Description: interventional procedure once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiviral therapy (lamivudine, other antiviral drugs)
Description: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
Study: NCT03451955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: Participants in the intervention group abstain from gluten for 6 months.
Study: NCT03504189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PregSense™
Description: PregSense™ wearable device will be applied for maternal-fetal monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiotocopraphy (CTG)
Description: Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
Study: NCT02796521

Intervention type: OTHER
Group type: OTHER
Intervention: dietary counseling
Description: Patients received individualized nutritional counseling encouraging them for enrichment

Intervention type: OTHER
Group type: OTHER
Intervention: dietary counseling
Description: Patients received individualized nutritional counseling encouraging them for enrichment

Intervention type: OTHER
Group type: OTHER
Intervention: nutritional workshop with enrichment during a meal
Description: Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
Study: NCT03286621

Intervention type: OTHER
Intervention: Administration of five eye-tracking paradigms
Description: All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.

Intervention type: OTHER
Intervention: Administration of five eye-tracking paradigms
Description: All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.

Intervention type: OTHER
Intervention: Administration of five eye-tracking paradigms
Description: All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
Study: NCT01398657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Androgen-Deprivation Therapy
Description: Short-term adjuvant androgen-deprivation therapy
Study: NCT01147562

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of biospecimen
Description: Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
Study: NCT02662335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Training
Description: Participate in Cogmed computerized working memory training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo standard follow-up care
Study: NCT02187237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YOLO TOUCH Low Level Laser
Study: NCT01240902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Description: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Description: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Description: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Description: Surgical Aortic Valve Replacement (SAVR)
Study: NCT03020277

Intervention type: OTHER
Group type: OTHER
Intervention: Ecological Momentary Assessment with Smartphone© Application
Description: Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
Study: NCT04356599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake
Description: The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
Study: NCT03845621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Mouthguard
Description: Use of a conventional custom-made mouthguard while playing water polo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Mouthguard
Description: Use of a conventional custom-made mouthguard while playing water polo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal-adjusted Mouthguard
Description: Use of an occlusal-adjusted custom-made mouthguard while playing water polo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal-adjusted Mouthguard
Description: Use of an occlusal-adjusted custom-made mouthguard while playing water polo
Study: NCT00583011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Local anesthesia: 2 cc of 1% Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo Group: 2cc Normal Saline
Study: NCT02358265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rupatadine on demand
Description: Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rupatadine
Description: Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg Rupatadine
Description: Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rupatadine on demand (sham updosing to 20 mg)
Description: Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
Study: NCT03259256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation of intrahepatic islet
Description: Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
Study: NCT01580826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pasteurization of mother's own milk
Description: mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
Study: NCT03803163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon Treprostinil
Study: NCT02588586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: 3BNC117 infusions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral Treatment Interruption
Description: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
Study: NCT02705378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxegol
Description: Intervention would be given by OG or NG tube
Study: NCT03343366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling Root Planing
Description: SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling Root Planing
Description: SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Oral Hygiene Instructions
Description: OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Instructions
Description: OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene Instructions
Description: OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
Study: NCT01481883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene Hydrochloride
Description: 120mg daily - 1 capsule daily for 12 week trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 12 week trial
Study: NCT00593424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat/High Carbohydrate
Description: Low Fat/High Carbohydrate for 6 week period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Monounsaturated Fat/Low Carbohydrate
Description: High Monounsaturated Fat/Low Carbohydrate for 6 week period
Study: NCT03321201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cauterization
Description: To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin glue
Description: Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
Study: NCT01923324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician telephone consultation
Description: Pain physician support for family physician treating patient

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual family physician care
Description: Usual family physician care without telephone consultation with pain physician
Study: NCT04521478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: quetiapine
Study: NCT04392219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIDD-2801
Description: Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.
Study: NCT02876861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical nephroureterectomy
Description: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical nephroureterectomy
Description: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal ureterectomy
Description: Distal ureterectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal ureterectomy
Description: Distal ureterectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
Study: NCT02962232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Releasing Peripheral Balloon Dilatation Catheter
Description: treatment group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA catheter
Description: control group
Study: NCT01463943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study: NCT01703169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
Study: NCT00195195

Intervention type: DRUG
Intervention: Sirolimus
Description: Transplantation patients treated with sirolimus who consent to participate in the study (register)
Study: NCT01207011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin hydrocloride
Description: AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
Study: NCT02360423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRE8 sirolimus-eluting stent
Description: The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESOLUTE zotarolimus-eluting stent
Description: The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
Study: NCT02822521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: A mobile health application that asks daily questions about participants' pain, function, and disease activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Population Management System
Description: Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
Study: NCT00315614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Transplantation and Bone Marrow
Description: Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
Study: NCT02372383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Anti-mycobacterial oral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Pancreatic enzyme replacement therapy
Study: NCT03176641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: Autologous platelet-rich plasma gel applied during meniscus repair surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Meniscus repair surgery only
Study: NCT02810704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Study: NCT02446548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
Study: NCT04145206

Intervention type: BEHAVIORAL
Intervention: Flamenco dance
Description: evaluation of ankle injuries in the flamenco dancers
Study: NCT01008774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Cooling Machine
Description: Scalp cooling procedures